Overview of Phenergan

Quick Facts

Property	Description
Active ingredient	Promethazine hydrochloride
Form	Tablets, Oral solutions, Suppositories, Injection
Pharmacological class	First-generation Antihistamine
General purpose	Anti-allergic, Anti-emetic, Sedative
Origin	Synthetic, Phenothiazine derivative

What Type of Medicine is Phenergan (Promethazine)?

Phenergan is the widely recognized trade name for the prescription medicinal substance Promethazine hydrochloride, which is fundamentally classified as a first-generation antihistamine. This synthetic compound, which is a phenothiazine derivative, operates primarily as an H1-receptor antagonist.

The compound belongs to a pharmacological class characterized by its ability to interfere with the chemical messenger histamine, which is released by the body during allergic responses. Promethazine is clinically recognized for its pronounced action on the central nervous system (CNS), resulting in its strong sedative properties. This difference defines Promethazine as a unique choice for situations where both anti-allergic action and calming are necessary, such as managing severe nocturnal itching associated with hives.

Composition and Forms of Promethazine

The medication is manufactured as a single active ingredient product, composed of Promethazine hydrochloride combined with inert ingredients tailored to the final physical form. Promethazine is available in a versatile array of dosage forms, including solid tablets and liquid oral solutions (syrup or elixir) for ingestion, as well as rectal suppositories and sterile injectable solutions. This comprehensive range of preparations facilitates multiple routes of administration, ensuring clinical utility across acute and non-acute care settings.

Phenergan’s General Purpose and High-Level Action

The high-level action of Promethazine is defined by its strong H1-receptor blockade combined with secondary effects on CNS chemical signals, giving it a triple function. The medication's general purpose is to provide relief for generalized anti-allergic conditions. Simultaneously, its significant influence on the CNS makes it effective as an anti-emetic agent for controlling nausea and as a sedative/hypnotic agent to induce calm or assist with temporary sleep.

What side effects are possible with Phenergan?

Possible Side Effects and Safety Information: Phenergan (Promethazine)

Phenergan's safety profile is defined by its effects as a central nervous system (CNS) depressant and its strong anticholinergic properties. Patients should be aware of serious warnings and common side effects.

Key Adverse Reactions and Contraindications

Serious and Fatal Risks: Phenergan is contraindicated in children under two years of age due to the potential for fatal respiratory depression. Caution is necessary when administering to children over two, and concomitant use with other CNS depressants is strictly limited. The injection form carries a specific warning for severe tissue injury, including gangrene, which may occur following intravenous, intra-arterial, or perivascular administration; the preferred route is deep intramuscular injection.

Common Adverse Reactions: The most common side effect is marked drowsiness or sedation, which can impair mental and physical abilities required for hazardous tasks like driving or operating machinery. Other frequent reactions are dry mouth, blurred vision, dizziness, or confusion. Patients should also avoid prolonged exposure to sunlight or tanning beds due to a risk of photosensitivity.

Other Significant Safety Considerations

System-Organ Class	Noteworthy Potential Adverse Reactions
Nervous System	Seizures (lowered threshold), Neuroleptic Malignant Syndrome (a rare but serious condition), extrapyramidal symptoms, and paradoxical excitation (restlessness, hyperactivity, or hallucinations, especially in children).
Cardiovascular	Hypotension (low blood pressure) and potential changes in heart rate.
Hematologic	Rare reports of blood dyscrasias, including leukopenia (low white blood cells) and agranulocytosis.

Phenergan is generally contraindicated in comatose states and in patients with lower respiratory tract symptoms, including asthma. Use requires caution in patients with conditions worsened by anticholinergic effects, such as narrow-angle glaucoma, prostatic hypertrophy, or stenosing peptic ulcer.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents classify Promethazine (Phenergan) overdose as a severe medical event necessitating immediate attention. The documented clinical presentation typically involves a combination of central nervous system (CNS) effects and pronounced anticholinergic toxicity.

CNS manifestations can range from deep drowsiness progressing to coma, or, paradoxically, hyperexcitability, agitation, hallucinations, and convulsions. Anticholinergic signs formally described include tachycardia (rapid heart rate), dilated pupils (mydriasis), dry mouth, and urinary retention.

Regulators emphasize the potential for severe, life-threatening outcomes, including fatal respiratory depression, cardiac arrhythmias, and severe circulatory collapse. The risk of sudden death at excessive dosages is a specific consideration in pediatric patients, who may initially display excitation and seizures. Elderly individuals are noted to be more susceptible to confusion and severe anticholinergic effects in overdose scenarios.

In the event of a suspected overdose, regulatory information mandates that an individual seek immediate medical attention or contact emergency services at once. As no specific antidote is known, the required management is entirely symptomatic and supportive. This official approach necessitates continuous monitoring of the patient's cardiovascular and respiratory status, often requiring specialized hospital observation.

Therapeutic Uses of Phenergan

The medication, which contains promethazine hydrochloride, is used across several therapeutic areas primarily focused on managing symptomatic discomfort and providing short-term supportive relief. It is applied in contexts where additional assistance is needed for stabilizing disruptive symptom manifestations.

Relief from Symptoms and Supportive Care

This medication is generally considered relevant for easing symptoms related to inflammatory or irritative states, such as those caused by allergic rhinitis, skin manifestations like hives (urticaria), and generalized itching (pruritus). Its clinical utility extends to the management of nausea and vomiting, as well as providing sedation.

The medication is commonly used across conditions presenting with acute episodes and for managing symptoms that interfere with daily comfort. Specifically, it is relevant for managing allergic symptoms, providing control of nausea and vomiting (including motion sickness and post-operative events), and facilitating short-term sedation or anxiety reduction before procedures. This application assists with managing the overall symptom load and supports the patient during difficult episodes.

“This medicine helps with managing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity.”

Quick Fact: Relief for Key Symptom Domains
Allergic Support: Helps manage pronounced itching, sneezing, and irritation related to inflammatory or irritative states.
Nausea Management: Applied in scenarios where nausea and vomiting (e.g., travel-induced) need symptomatic assistance.
Sedation Support: Helps manage symptoms of restlessness or tension when temporary functional stability is affected.

Regulatory References

PROMETHAZINE HYDROCHLORIDE tablet - DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Phenergan (Promethazine) — Official Regulatory Information

Contraindicated Populations

Promethazine is absolutely prohibited for use in specific populations, as mandated by regulatory bodies like the FDA and EMA. It is contraindicated for all pediatric patients less than two years of age due to the potential for fatal respiratory depression [Source 1.1]. Absolute prohibition also applies to patients in comatose states, in individuals with a known hypersensitivity to promethazine or other phenothiazines, and for treating lower respiratory tract symptoms, including asthma [Source 1.4]. Oral forms are generally contraindicated for children under six years of age in several international regions due to the risk of psychiatric and CNS side effects [Source 1.3, 1.5].

Restricted and Conditional Use

Use is restricted in several populations where caution is mandatory. It is not recommended for use in women who are breastfeeding or during late pregnancy [Source 1.2]. In adults, caution is required for the elderly due to heightened susceptibility to anticholinergic effects and confusion [Source 1.6]. Caution is also necessary for patients with certain pre-existing conditions, including seizure disorders, cardiovascular disease, hepatic impairment, or renal insufficiency [Source 1.1, 1.2]. Regulatory documents advise that use should be avoided in patients with compromised respiratory function, such as those with sleep apnea [Source 1.6].

Official Eligibility Statements

The medicine is contraindicated for use in children under two years of age.
It is contraindicated in patients with comatose states or asthma.
Use requires caution in the elderly and patients with seizure disorders.
Use is generally not recommended during pregnancy and lactation.

Connection to the overall eligibility profile

The official regulatory profile strictly defines who can and cannot use the medicine by establishing absolute age prohibitions and defining several condition-based contraindications [Source 1.1]. For all other eligible populations, use is often subject to mandatory caution when underlying conditions like hepatic or renal impairment are present, thereby restricting the circumstances of use as documented in the drug's regulatory label [Source 1.6, 2.4].

What should I know about interactions with other medicines?

The official interaction profile for promethazine is defined by significant risks of additive effects and altered drug exposure documented in regulatory labeling. Promethazine is contraindicated with certain medicines, including Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of their cessation, due to the risk of potentiation. The drug is also prohibited for use with agents known to prolong the QTc interval, such as Pimozide and Sotalol, to mitigate cardiac risks.

A major concern is additive Central Nervous System (CNS) depression. Promethazine may increase, prolong, or intensify the sedative action of co-administered CNS depressants, including alcohol, opioids/narcotics, barbiturates, and tranquilizers. Regulatory documents require that the dose of barbiturates be reduced by at least one-half, and the dose of narcotics by one-quarter to one-half, when co-administered.

A separate pharmacokinetic interaction occurs with strong CYP2D6 inhibitors, such as Mavorixafor, which results in a documented increase in promethazine exposure. Procedural constraints require promethazine to be discontinued at least 72 hours before Allergen Skin Tests as it interferes with the histamine response. Additionally, caution is noted regarding additive hypotensive effects when administering promethazine with antihypertensives in the elderly population.

Mechanism of Action

Multi-Target Receptor Blockade

Promethazine functions as a non-selective competitive antagonist by binding to and blocking Histamine H1 receptors centrally and peripherally. Crucially, its mechanism is broader, extending to antagonize D2 Dopamine and Muscarinic Acetylcholine receptors, and consequently engages multiple systems involved in arousal and autonomic regulation.

CNS Penetration and Arousal Suppression

The drug's high lipophilicity ensures its rapid and extensive passage across the blood-brain barrier ( BBB), leading to significant action on CNS targets. This central blockade of H1 receptors in the arousal centers directly modifies signaling sequences that maintain wakefulness, which results in reduced neuronal excitability, leading to the physiological consequences of somnolence and CNS depression.

Anti-Emetic Pathway Interruption

The non-selective mechanism is applied to disrupt the body's emetic (vomiting) reflex arc at key regulatory points. By blocking D2 receptors in the Chemoreceptor Trigger Zone ( CTZ) and Muscarinic receptors in the brainstem's Vomiting Center, the mechanism interrupts afferent signaling to the reflex, which produces a suppression of the vomiting pathway.

Dosage and Administration Information

How Promethazine (Phenergan) is Used

The usage of promethazine is defined by its approved administration routes and context-specific dosing schedules. The medication is available in various forms, including tablets and oral solutions for ingestion, rectal suppositories, and sterile injectable solutions.

Administration Routes and Safety Constraints

Promethazine is administered via the oral, rectal, or parenteral routes. For injectable solutions, deep intramuscular (IM) injection is the preferred method. Intravenous (IV) administration is highly restrictive, requiring the solution to be diluted to a maximum concentration of 1 mg/mL and infused slowly into a large, running vein to minimize the risk of irritation. The drug is explicitly prohibited from being administered via the subcutaneous or intra-arterial routes.

Official Dosing Patterns and Frequency

Administration frequency follows distinct patterns based on the symptomatic need:

Once-Daily Use: For allergic symptoms or temporary sedation, adults typically receive 25 mg (or up to 50 mg) as a single dose, usually taken at bedtime.
Divided Use: For continuous allergy management, a regimen of 12.5 mg before meals and at bedtime may be used.
As-Needed (PRN) Use: For acute nausea and vomiting, adult doses typically range from 12.5 mg to 25 mg, administered every 4 to 6 hours as required.

The oral form may be taken with food, water, or milk to lessen potential gastrointestinal discomfort.

Population and Procedural Rules

Promethazine is contraindicated in children under two years of age. For pediatric patients aged 2 years and older, dosing for certain indications is calculated based on weight. A key procedural rule for concomitant therapy states that the doses of concurrent central nervous system depressants must be reduced by one-quarter to one-half when promethazine is administered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Phenergan

This overview provides a summary of the clinical research conducted on promethazine, the active ingredient in Phenergan, based on available trial data and regulatory documents. This summary focuses only on what researchers studied and the patterns they reported, without offering medical advice or treatment recommendations.

Evidence for use in Allergic Conditions and Skin Symptoms

Promethazine was studied in research contexts exploring how symptoms change over time in conditions characterized by outcomes linked to inflammatory or irritative states, such as seasonal allergic symptoms and hives. The research base consists of short-term Randomized Controlled Trials (RCTs) and controlled clinical pharmacology studies that often compare Promethazine against either a placebo or active control agents.

Studies were applied in research contexts involving fluctuating or unstable symptoms, examining how symptoms evolved in adult patients. Researchers monitored patient-reported outcomes describing perceived discomfort and observed the compound’s effects on histamine-induced skin reactions. Findings describe patterns observed in these short-term studies, reporting measured changes in subjective symptom reports and physiological responses within the observed populations.

What remains uncertain is the scope of long-term outcomes when the compound is used for managing chronic allergic conditions. Follow-up durations were limited, focusing primarily on immediate, acute effects. Furthermore, comparative evidence is lacking against many newer classes of non-sedating anti-allergy medications for extended periods of use, indicating that certainty remains low regarding the full context of long-term use patterns.

Evidence for use in Nausea and Vomiting Control

Promethazine was evaluated in managing episodic or acute changes related to nausea and vomiting. The research base consists of numerous Randomized Controlled Trials (RCTs) and systematic reviews, with studies conducted during research exploring short-term symptom changes in acute settings, such as following surgical procedures.

Research examined outcomes related to systemic or functional imbalance, specifically monitoring the frequency of vomiting episodes and the severity of nausea using patient-reported scales. Trials reported how symptoms evolved in the observed populations, and data describe patterns related to the need for rescue medication in certain acute scenarios. Findings varied across different study designs, particularly in trials where Promethazine was evaluated against active control compounds.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Phenergan (FAQ)

Q: How quickly do the effects of Phenergan typically begin?

According to official product information, the effects of the medicine typically begin quickly. After taking it by mouth or receiving an injection into a muscle, effects are usually apparent within 20 minutes. If administered directly into a vein, the effects may start within about five minutes.

Q: How long does the effect of Phenergan generally last in the body?

The duration of the medicine's effect generally lasts between four to six hours. However, official regulatory documents note that in some people, the effects may persist for up to 12 hours.

Q: Can Phenergan be used for different types of allergies?

Official information indicates that this medicine is used for managing a variety of allergic conditions. This includes symptoms associated with seasonal allergies and various skin-related irritations.

Q: Are there any specific foods or drinks that interact with Phenergan?

Official product information does not list specific foods that must be avoided while using this medicine. It is described that the medication may be taken with food, milk, or water, as this may help lessen potential gastrointestinal discomfort.

Q: Can taking Phenergan cause unusual dreams or nightmares?

Regulatory patient guides note that vivid dreams or nightmares are listed as a possible adverse reaction to the medicine. This is a recognized side effect that is documented in official patient information.

Q: Is there a risk of becoming dependent on Phenergan?

According to US regulatory guidance, promethazine alone is not classified as a controlled substance. However, the product's sedative properties, particularly when used outside of medical instruction or combined with other CNS depressants, have been associated with a potential for psychological dependence.

Q: Is Phenergan commonly used for motion sickness?

Yes, the medicine is explicitly indicated in regulatory prescribing information for both the prevention and treatment of motion sickness. The official documents include specific dosing recommendations related to this purpose.

Q: What is the safety classification of Phenergan in official documents?

Promethazine as a single active ingredient is not classified as a controlled substance under the US Drug Enforcement Administration (DEA). However, in the US, certain cough syrups that combine promethazine with an opioid like codeine are regulated as Schedule V controlled substances.

Q: Do official sources discuss any potential for withdrawal effects from Phenergan?

Official regulatory patient guides note that after using the medicine for a long period, stopping it suddenly may result in potential symptoms. These symptoms may include dizziness, sweating, nausea, a racing heart, or difficulty sleeping. Regulatory documents note that slow discontinuation is described as a strategy to help prevent these effects.

Q: Are there official statements about the maximum length of time Phenergan should be used?

Official regulatory patient information advises that the medicine should typically not be used for longer than 7 to 10 days continuously. If symptoms persist or worsen after this time, the documents indicate that consultation is advised.

Q: How is Phenergan typically used in a hospital setting?

In acute care and hospital environments, the medicine is frequently used for the management of acute nausea and vomiting. Regulatory information also describes its role in providing sedation both before and after surgical procedures.

Q: What are the signs of taking too much Phenergan, as described in official documents?

Official patient documents describe that taking too much of the medicine may lead to severe reactions. These may include profound drowsiness, agitation, confusion, seizures, or problems with breathing, heart rate, and blood pressure.

Q: What is the official guidance on taking Phenergan if a dose is missed?

Official patient guidance on missed doses advises different approaches depending on the purpose. For motion sickness, regulatory guidance indicates that the medicine is to be taken as soon as it is remembered. For other uses, the guidance generally describes skipping the missed dose and returning to the next scheduled dose at the usual time. The regulatory advice is explicit to never take two doses together.

Q: Can Phenergan interact with herbal supplements?

Official patient information describes that consulting a professional before combining this medicine with herbal remedies or supplements is generally recommended. This caution is noted because some supplements may increase side effects such as drowsiness or dry mouth, potentially worsening these known effects of the medication.

Q: Does Phenergan interact with caffeine?

Regulatory guidance focuses on the risk of combining a Central Nervous System (CNS) depressant like this medicine with CNS stimulants, which includes caffeine. This combination may result in counteracting effects or increase the potential for cardiovascular risks, according to official information.

Q: Are there different brand names for the drug promethazine?

Promethazine is the active ingredient and chemical name for the medicine. According to official databases and regulatory information, it is marketed under various trade names globally, including Phenergan, as well as others such as Prorex, Provigan, and Zipan.

Q: How is Phenergan described for managing surgical anxiety?

Official prescribing information states the medicine is used to provide sedation both before and after surgical procedures. This use is described in the context of managing anxiety and helping to control pain when it is administered alongside reduced doses of pain relief medication.

Q: What is meant by the 'anticholinergic' effects of Phenergan?

The term 'anticholinergic' refers to the medicine's action of blocking a specific chemical messenger in the body. This mechanism is responsible for certain side effects, such as dry mouth and blurred vision, which are noted in official prescribing information.

Q: What does the research say about the use of Phenergan as a sleep aid?

Official prescribing documents classify the medicine as a sedative/hypnotic agent. It is approved for use as a single dose, often taken at bedtime, to provide temporary sedation and manage conditions like acute allergic symptoms that are difficult to control at night.

Q: Can Phenergan be taken with common pain relievers?

Official regulatory patient guides state that the medicine may be taken with common, non-opioid pain relievers such as paracetamol (acetaminophen) or ibuprofen. However, patient information documents note that care is needed to avoid redundant dosing if the promethazine product already contains a pain reliever.

How should Phenergan be stored and disposed of?

Phenergan (promethazine hydrochloride) must be stored according to its specific dosage form and official regulatory requirements.

Official Storage and Handling

Dosage Form	Required Storage Condition	Protection Rules
Tablets & Injection	Controlled Room Temperature (20 to 25 C)	Protect from light; store injection in its carton.
Suppositories	Refrigerated (2 to 8 C)	Do not freeze.

The tablets and oral solutions must be protected from excess heat and moisture. The injection solution must be discarded if any discoloration or precipitate is observed, as this indicates instability. All forms must be kept out of the reach of children, and tablets should have a child-resistant closure.

Disposal Instructions

Expired or unused medicine should be disposed of through a drug take-back program. If a program is unavailable, the product must be mixed with an undesirable substance (e.g., dirt or coffee grounds) and sealed in a bag for household trash. Promethazine is not on the list of medicines approved for flushing down the toilet.

Phenergan